Kymera Therapeutics (KYMR) Net Income towards Common Stockholders (2019 - 2026)

Kymera Therapeutics (KYMR) has 8 years of Net Income towards Common Stockholders data on file, last reported at -$69.2 million in Q1 2026.

• On a quarterly basis, Net Income towards Common Stockholders fell 5.57% year-over-year to -$69.2 million in Q1 2026; TTM through Mar 2026 was -$315.0 million, a 30.77% decrease from a year earlier, with the FY2025 full-year figure at -$311.4 million, down 39.08% from the prior year.
• Net Income towards Common Stockholders for Q1 2026 stood at -$69.2 million, up from -$87.0 million in the prior quarter.
• Over the last five years, Net Income towards Common Stockholders for KYMR reached as high as -$14.4 million in Q4 2023 and fell as low as -$168.5 million in Q1 2022.
• Historically, Net Income towards Common Stockholders has averaged -$61.1 million across 5 years, with a median of -$52.9 million in 2023.
• On a YoY basis, Net Income towards Common Stockholders climbed as much as 84.09% in 2022 and fell as far as 1188.61% in 2022.
• Year by year, Net Income towards Common Stockholders stood at -$34.9 million in 2022, then surged by 58.79% to -$14.4 million in 2023, then tumbled by 392.43% to -$70.8 million in 2024, then decreased by 22.94% to -$87.0 million in 2025, then increased by 20.4% to -$69.2 million in 2026.
• Per Business Quant data, the three most recent Net Income towards Common Stockholders figures were -$69.2 million in Q1 2026, -$87.0 million in Q4 2025, and -$82.2 million in Q3 2025.